"The validation process has been completed, and the unit is ready to start manufacturing insulin on January 15," said Ali Aoun.
The Biotherapeutics unit has been built by Algeria company Biocare.
Aoun said importing insulin cost the country $425 million (£350 million) last year.
Local production is estimated to cover 50% of the demand.
At least 15% of Algeria's population, that is, 2.8 million people, are diabetic, according to the Ministry of Health.
They estimate that the number could double by the year 2030.
Globally, the International Diabetes Federation estimates the number of people with diabetes at 537 million, and that half of them are not aware of their condition.
--BBC--